Seeking Alpha

Oppenheimer reiterates a Buy on Questcor Pharmaceuticals (QCOR) following talks with U.S....

Oppenheimer reiterates a Buy on Questcor Pharmaceuticals (QCOR) following talks with U.S. nephrologists who have experience with its Acthar MS drug. The firm believes the biggest headwind facing Acthar adoption is physician awareness, which it expects will be addressed by sales force expansion and new studies. Questcor was recently hit by a weak monthly sales report for Acthar.
Comments (1)
  • Ernest P Icahn
    , contributor
    Comments (378) | Send Message
     
    According to the website expenses to be 20-25% higher in 1st & 2nd Q than was in Q4. Training new sales reps & new Docs Lupus experiments may cost up to $7,200,000 extra per Q. That can mean a loss of as much as $0.11 EPS or slowing to a 4.2% Sequential EPS Growth Rate. -Ernest
    20 Mar 2012, 02:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs